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Comparison of transcatheter aortic valve implantation versus surgical aortic
valve replacement in a high-risk patient population : a propensity score analysis
Lenard Conradi, Moritz Seiffert, Hendrik Treede, Miriam Silaschi, Stephan Baldus,
Johannes Schirmer, Stefan Blankenberg, Hermann Reichenspurner
University Heart Center Hamburg, Hamburg, Germany
Background: Transcatheter aortic valve implantation (TAVI) has recently been
advocated to decrease perioperative risk in high-risk patients. In this propensity-score
analysis we compared outcomes after TAVI to those after surgical aortic valve
replacement (AVR).
Methods: From June 2009 through June 2010, 82 consecutive patients underwent
TAVI via a transapical (n=60) or transfemoral (n=22) approach using the
EdwardsSAPIENTM prosthesis. Mean patient age was 81.9±5.2 years, 64.6% were
females. Logistic EuroSCORE was 23.6±1.4% and STS score was 8.7±1.3%. A group
of 82 patients after surgical AVR was retrieved from our database yielding a control
group that was matched to the cases with respect to baseline demographics and typical
risk factors.
Results: Overall mortality did not differ significantly between TAVI and AVR groups
at 30 days (7.3% vs. 8.6%), 90 days (13.6% vs. 11.1%) or 180 days (17.8 vs. 18.9%,
p=0.889). Conversion to surgery was necessary in 2 TAVI cases (2.4%). Perioperative
stroke occurred in 2 cases per group (2.4%). Pacemakers were implanted for new-onset
heart-block in 3.7% and 2.4% in the TAVI and AVR group respectively (p=1.0). TAVI
resulted in shorter operative times (p<0.001), shorter ventilation times (p<0.001) and
shorter length of stay in the intensive care unit (p=0.008). Duration of hospital stay
however was not significantly different (p=0.11).
Conclusion: In our experience, mortality rates are similar after both types of procedure.
Patients receiving TAVI benefit from faster postoperative recovery. Until more clinical
data become available, the optimal procedure has to be determined for each patient
according to individual risk factors.
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Background: : The absence of uniformity in endpoint definitions challenges the
comparison between previously reported major adverse cerebro- and cardiovascular
event rates after Transcatheter Aortic Valve Implantation (TAVI). To address this, in
2009 the Valve Academic Research Consortium (VARC) was established aiming to
provide standardized endpoint definitions for TAVI clinical trials. In this study, we
sought to determine the occurrence of in-hospital complications after TAVI according
to the VARC criteria in addition to the Length of Stay (LOS).
Methods: Between November 2005 and September 2010, we prospectively enrolled
150 consecutive patients who underwent TAVI with the Medtronic CoreValve System
in our institution. Complications, prosthetic valve associated endpoints and therapy-
specific endpoints were defined according to the definitions provided by the VARC.
Results: The mean age (±SD) was 81 (±7) years and 55% were female. Thirty day or
in-hospital mortality was 11% and the 30-day combined safety endpoint was 22%.
Seventy-six patients (51%) had ≥1 cardiovascular and/or non-cardiovascular
complication of whom 16 also underwent a new permanent pacemaker implantation
(PPI). In the 74 patients with uneventful TAVI, 12 patients (8%) underwent PPI. TAVI
was truly uneventful in 62 patients (41%). Bleeding complications were observed most
frequently (31%), followed by acute kidney injury (18%), vascular complications
(16%) and stroke/ TIA (11%). The median LOS in patients with a complicated and a
truly uncomplicated TAVI was 14.0 (8.0-20.5) and 8.0 (7.0-10.8) days, respectively
(p<0.001).
Conclusion: TAVI was associated with ≥1 cardiovascular and/or non-cardiovascular
event in 51% of the patients; new PPI was needed in another 8% and TAVI was truly
uncomplicated in 41%. Complications and need for new PPI significantly prolonged
LOS.
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B-Type Natriuretic Peptide Predicts Improvement of Left Ventricular Function
and Clinical Outcome After Balloon Aortic Valvuloplasty
Joelle Kefer, Jean-Marie Gapira, Amer Harmouch, Jim Reish, Jean Renkin
cliniques saint-luc,university of louvain, Brussels, Belgium
Background: Percutaneous balloon aortic valvuloplasty (PBAV) is a therapeutic
option for patients with aortic stenosis and poor left ventricular ejection fraction
(LVEF). B-Type natriuretic peptide (BNP) predicts outcome of patients treated by
aortic valve replacement.
Methods: Among 155 consecutive patients treated in our institution by PBAV, 60 had
a LVEF < 40% and underwent an echocardiography at 1 month. A significant
improvement of LVEF was defined as an increase of at least 10% of LVEF at 30 days.
BNP was measured before and 24 hours after PBAV.
Results: In our 60 patients (39 males, 83 ± 7 years, logistic Euroscore 46 ± 22%),
aortic valve area increased from 0.5 ± 0.2 to 0.9 ± 0.3 cm squarre and the mean gradient
decreased from 31 ± 14 to 16 ± 9 mmHg (p<0.0001 for both) after PBAV. BNP plasma
levels decreased from 2017 ± 1332 to 1561 ± 1097 pg/ml (p=0.001) at 24 hours. A
significant improvement of LVEF was observed in 48% of patients (group 1, N=29)
from 27 ± 6 % to 45 ± 6 % (p<0.0001) and remained unchanged among 31 other
patients (group 2) from 28 ± 8 % to 28 ± 11 % (p=NS). Although clinical data, LVEF
(27 ± 6 vs 28 ± 8; p=0.32) and BNP plasma levels (1861 ± 1067 vs 2201 ± 1665;
p=0.24) were similar at baseline between group 1 and 2 respectively, a significant
reduction of BNP at 24 hours was only observed in group 1 (-711 ± 604 in group 1 vs
+43 ± 742 in group 2; p=0.004). By multivariate analysis, BNP reduction > 300 pg/ml
was independant predictor of LVEF improvement at 30 days (hazard ratio : 2.825; 95%
confidence interval : 1.225-6.513; p = 0.01). Kaplan-Meier analysis showed that 1-
year survival after PBAV was significantly higher in group 1 than in group 2 patients
(87 ± 7 vs 48 ± 11 %; p=0.002).
Conclusion: Reduction of BNP 24 hours after PBAV is a strong predictor of LVEF
improvement at 30-day. Survival at 1 year was significantly higher in patients with
such an improved LVEF after PBAV.
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Background: Data from Cohort A of the PARTNER trial demonstrated that
transcatheter and surgical aortic-valve replacement (AVR) were associated with
different periprocedural risks but similar survival rates at 1-year. However, this study
was performed with the earlier version of the transcatheter device in centers with no
previous experience with the procedure. There are limited data comparing the latest
generation Edwards SapienXT prosthesis and Novaflex delivery system (Edwards
Lifesciences, Irvine, California) which require larger size arterial sheaths.
Methods: We identified 60 consecutive patients who underwent transcatheter AVR
(TAVR) with the SapienXT THV via the transfemoral route between April 2010-
January 2011. We then utilized propensity score matching to identify 60 high-risk
historical case controls who underwent surgical AVR (SAVR) between August 2003-
July 2008. Valve Academic Research Consortium (VARC) definitions were applied
for endpoint adjudication in both groups.
Results: The TAVR and SAVR were well matched for baseline clinical characteristics,
including EuroScore (10.4±2.9 vs. 10.8±2.5; p=0.38) and STS score (5.7±5.3 vs.
5.5±3.1; p=0.76). Vascular complications were more common in the TAVR group (25%
vs. 1.7%; p<0.001). SAVR was associated with a higher rate of VARC-defined bleeding
80% with 58.3%; p=0.1), blood transfusion (58.3% vs. 31.7%; p=0.003), and number
of blood units transfused (2.3±3.4 vs. 1.1±2.0; p=0.02). Similarly, acute kidney injury
(58.3% vs. 28.3%); p=0.001) and periprocedural TIA (11.7% vs. 1.7%;p=0.03) were
more frequent with SAVR. Although in-hospital stroke (3.3% vs. 1.7%) and mortality
(6.7% vs. 3.3%) were numerically higher after SAVR, these differences were not
statistically different (p>0.05). The average length of stay was longer after SAVR
(9.9±9.6 vs. 7.0±5.9 days; p=0.05).
Conclusion: In this retrospective case-control study of real-world patients undergoing
transcatheter and surgical AVR, these procedures were associated with different
periprocedural risks. These data mirror those of the PARTNER trial, except for a lower
risk of TIA and acute kidney injury with TAVR. Longer follow-up data will be
presented at TCT 2011.
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The Effects of Pre-existing Significant Coronary Artery Disease Defined by
QCA Analysis Upon Outcome After Transcatheter Aortic Valve Implantation
Using the Edwards Bioprosthesis
Muhammed Zeeshan Khawaja1, 2, Kaleab Asress1, 2, Hari Haran2, Imad Nadra3,
Karen Wilson1, Kirsty MacGillivray1, Jane Hancock1, Christopher Young1, Vinayak
Bapat1, Simon Redwood1, 2, Martyn Thomas1
1Cardiology, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom;
2King’s College, London, London, United Kingdom; 3Nottingham University
Hospitals NHS Trust, Nottingham, United Kingdom
Background: Patients undergoing surgical aortic valve replacement (sAVR) routinely
undergo simultaneous coronary artery bypass grafting (CABG) for significant coronary
artery disease (CAD) due to adverse prognostic impact. Whilst manufacturers advise
percutaneous intervention (PCI) to significant CAD prior to transcatheter aortic valve
implantation (TAVI) there is considerable variation amongst operators. We sought to
analyse the impact of CAD in our centre’s patients.
Methods: We performed a retrospective analysis of 164 patients who underwent TAVI
using the Edwards bioprosthesis from March 2008 to October 2010. 6 angiograms
were not available for analysis. Patients were classified using pre-TAVI quantitative
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